Burnet + HIV
HIV is a major focus at Burnet, with more than half our work addressing laboratory-based research into finding a cure for the disease while our public health programs are focused on education and prevention both in Australia and overseas.
Nearly 37 million people are living with HIV.
Sub-Saharan Africa is the most affected region with more than 25 million people affected, and accounts for over 65 percent of the global total of new HIV infections. Tragically, HIV claims the lives of 1.1 million people each year globally.
The human immunodeficiency virus (HIV) infects cells of the immune system, causing it to become weak and making it more susceptible to infections. HIV is generally spread through unprotected sexual intercourse or contaminated blood, but can also be spread from mother to child during pregnancy. There is no cure for HIV.
Acquired immunodeficiency syndrome (AIDS) is the most advanced stage of HIV infection. It can take 10-15 years for an HIV-infected person to develop AIDS but antiretroviral (ARV) drugs have made a huge difference in slowing or halting the progression to AIDS.
The World Health Organization (WHO) estimates more than 36 million people are living with the virus, with 2.1 million new infections (of which 20 percent are of adolescent girls and young women aged 15-24) and 1.1 million people dying from AIDS-related illnesses each year. It is estimated that currently only 51 percent of people with HIV know their status. The WHO reports that In 2015, 17 million people living with HIV were receiving antiretroviral therapy (ART) globally, of which 10.3 million were in eastern and southern Africa.
**World AIDS Day - 1 December
World AIDS Day, held each year on 1 December, is an opportunity for people worldwide to show their support for people living with HIV and to commemorate those who have died.
- A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression
Investigating a novel plasma biomarker's potential for identifying gut leakage.
- Accelerating ART initiation (AAMI Study)
This project will trial the POC VISITECT® CD4 test and POC LYNX HIV p24 early infant diagnostic test.
- ACCESS - STI and BBV surveillance system
ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
- Access Point Of Care
Increasing access to life-saving treatments for infectious diseases through point-of-care tests.
- Altered States: An evaluation of VAC drug and alcohol services
An evaluation of drug and alcohol services at the Victorian AIDS Council targeting GLBTI individuals.
- APPRISE - Centre for Research Excellence
The Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE).
- Big Day Out studies: Sex, Drugs, and Rock'n'Roll
A landmark study since 2005 of young people's risk behaviours including sex, drug use and alcohol.
- Broadly neutralising anti-HIV antibodies and Fc Receptor function
Defining the properties of anti-HIV antibodies for vaccine development and protection of pregnant women.
- Centre for Research Excellence into Injecting Drug Use
Improving the health of PWID through new research to inform public health policy and practice.
- Characterisation of drug resistance mutations in the HIV reverse transcriptase
The role of mutations selected during antiretroviral therapy on HIV drug resistance and viral fitness.
- Characterisation of Viral Tropism Alterations During Progressive Subtype C HIV-1 Infection
How Subtype C HIV-1 viruses target and infect different cells in the human immune system.
- co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
- DARE C: ATAHC II Substudy
DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
- Developing new HIV disease progression tests
This project will develop prognostic tools to identify HIV+ persons at risk of rapid disease progression.
- Development of a novel prophylactic vaccine candidate for HIV-1
A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission.
- Development of plasma separation and collection for HIV viral load testing
Aimed at improving access to HIV viral load assays in resource-limited settings.
- e-TEST: Enhancing STI/HIV testing in high-risk gay men
eTEST is an intervention and surveillance system that aims to increase STI/HIV testing.
- Enhancing education to reduce harms associated with drug use in Yangon, Myanmar
This project is supporting harm reduction and health care for people who inject drugs and who use drugs.
- Feasibility of antiretroviral treatment monitoring in the era of decentralised HIV care
A review to assess antiretroviral treatment monitoring in settings of decentralised HIV care.
- Healthy Mothers, Healthy Babies
A collaborative research program aimed at providing life-saving health care for women and children in PNG.
- HIV Clinical Training for Doctors
HIV Clinical Training for doctors in urban and rural locations in resource constrained countries.
- HIV mitigation for people who inject drugs in Myanmar
Aims to prevent the transmission of HIV among young people, students, migrant and transport workers. Priority areas include the prevention of the transmission of HIV through unsafe behaviour in sexual contacts and injecting drug use.
- HIV Prevention Initiatives Evaluation
An initiative to reduce HIV/STI risk behaviours as well as increasing health seeking behaviours among homosexually active gay men.
- HIV reverse transcriptase structure function and role in HIV replication
To study the role of reverse transcriptase dimerization in HIV replication.
- HIV services for young key populations in the Philippines
The Philippines is considering changing laws that require adolescents to seek parental consent for HIV testing. This project will explore options and contribute to better understanding of how new laws might result in improved practices.
- HIV-associated neuropathy (HIV-SN): epidemiology and genetics
HIV-associated neuropathy (HIV-SN) is a very common cause of pain in the lower limbs for people with HIV. Understanding which patients are at risk will assist preventing and treating this disabling condition.
- Intrinsic vaginal factors and their Impact on HIV and other sexually transmitted infections
This study seeks to determine the impact of vaginal microbiota metabolites on immune mediators and how they influence infection with HIV and other sexually transmitted infections.
- Laboratory Strengthening in Asia Pacific region
Laboratory tests are needed to guide the use of vital antiretroviral therapy (ART) in HIV infection, however laboratories in developing countries are not ready to perform the sophisticated tests to guide who needs treatment
- Mechanism of action of dendrimer microbicides against HIV
This study will lead to a greater understanding of how dendrimer nanoparticles can block HIV infection.
- New drugs for HIV prevention: novel inhibitors against an essential HIV target
The research activity addresses the urgent need for new types of antiviral drugs for preventing HIV transmission.
- Opportunities to improve the health of behaviourally bisexual men in Vientiane, Laos
Men with bisexual behaviour in Laos engage in high-risk behaviours with low access to sexual health care.
- Optima decision science
Research and applications across a range of disease areas to improve allocative efficiency (the maximization of health outcomes using the most cost-effective mix of interventions and implementation methods).
- Papua New Guinea health system strengthening roles
Burnet is a partner in the Australian government-supported Health and HIV Implementation Services Provider (HHISP). HHISP is the main support to the large health development partnership of the Australian and PNG governments.
- PATH Cohort Study
A cohort study of the trajectories of prisoners with a history of injecting drug use after release from prison
- Physical activity and HIV
Non-drug treatments may have important health benefits for people living with chronic illnesses. This project aims to understand the role of physical activity for improving health for those with HIV.
- Preclinical Clinical Evaluation of Candidate Microbicides
We are evaluating dendrimer nanoparticles as microbicides to prevent HIV and other sexually transmitted infections.
- PRONTO! Community-based Rapid HIV Testing Service
The first rapid HIV test service in Victoria targeting gay men and men who have sex with men.
- Resources for improving national responses to HIV and STIs
These resources aim to build country leadership of more effective responses to the HIV and STI epidemics.
- Scaling Up of Most at Risk Populations Component II (SUM II)
Over five years, this project aims to improve the performance of Indonesian civil society organisations (CSOs) in servicing those in the population that are most at risk of HIV and AIDS
- The Melbourne Injecting Drug User Cohort Study (SuperMIX)
A five-year study of the dynamics of cessation of injecting drug use and any subsequent relapse.
- The Victorian Primary Care Network for Sentinel Surveillance on BBVs and STIs
The Victorian Primary Care Network for Sentinel Surveillance of BBVs and STIs (VPCNSS) commenced operation in April 2006.
- Transmitted and acquired drug resistant HIV strains in Victoria, Australia
This project aims to document the rates and types of mutations associated with drug resistance being acquired by Victorian patients diagnosed with HIV and how this is changing over time.
- Victorian Pre-exposure Prophylaxis (PrEP) Demonstrations
This prevention strategy involves people who are HIV-negative taking HIV treatment medications to reduce their risk of acquiring HIV.
- Virucidal activity of lactic acid and other carboxylic acids in the vagina against viral STIs
To understand how lactic acid inactivates HIV and other viral STIs.
- VISITECT® CD4
An affordable HIV point-of-care test developed by Burnet but licensed to Omega Diagnostics.
- Working with men to address HIV in Myanmar
Ensuring high quality HIV prevention services for hard to reach men who have sex with men (MSM). The project aims to reduce HIV-related risk, vulnerability and impact among MSM and their sexual partners.